Biochemical scaffolds for treating menopausal symptoms. The biochemical scaffolds include a base liquid medium, a bioenergetic platform and a vibrational platform. The bioenergetic platform includes at least one Krebs cycle modulator and/or neurotransmitter modulator and/or nuclear hormone receptor modulator. The vibrational platform includes at least one energy signature component, e.g., an herb. The biochemical scaffold is subjected to sequential harmonic oscillation for a defined, predetermined period of time, wherein the energy signature of the energy signature component is imparted to, captured, replicated, and retained by the liquid medium, and, when the biochemical scaffolds are delivered to and, thus, in communication with biological tissue, the biochemical scaffolds induce specific biochemical activities via the resonant transfer of the retained energy signature to the biological tissue and, hence, endogenous cells thereof.

The invention discloses a traditional Chinese medicine mixture with a function of promoting directional differentiation of stem cells into cardiomyocytes, which comprises syngnathus, cornu cervi pantotrichum, hippocampus, ginseng, astragalus, epimedium, placenta hominis, salvia miltiorrhiza, gynostemma pentaphyllum and saussurea involucrata. The invention discloses a traditional Chinese medicine effective ingredient compound with a function of promoting directional differentiation of stem cells into cardiomyocytes. The invention further discloses a chemical compound with a function of promoting directional differentiation of stem cells into cardiomyocytes, which is a brand-new chemical compound from a mixture of velvet antler polypeptide, a syngnathus extract and a hippocampus extracta new isomer of iridoid glycoside Scropolioside D. The invention further discloses uses of the mixture, the compound and the chemical compound in preparation of a drug or a kit for promoting directional differentiation of stem cells into cardiomyocytes and in scientific research.

The invention discloses a traditional Chinese medicine mixture with a function of promoting directional differentiation of stem cells into cardiomyocytes, which comprises syngnathus, cornu cervi pantotrichum, hippocampus, ginseng, astragalus, epimedium, placenta hominis, salvia miltiorrhiza, gynostemma pentaphyllum and saussurea involucrata. The invention discloses a traditional Chinese medicine effective ingredient compound with a function of promoting directional differentiation of stem cells into cardiomyocytes. The invention further discloses a chemical compound with a function of promoting directional differentiation of stem cells into cardiomyocytes, which is a brand-new chemical compound from a mixture of velvet antler polypeptide, a syngnathus extract and a hippocampus extracta new isomer of iridoid glycoside Scropolioside D. The invention further discloses uses of the mixture, the compound and the chemical compound in preparation of a drug or a kit for promoting directional differentiation of stem cells into cardiomyocytes and in scientific research.

A method and formulation for delivering a PDE-5 inhibitor in a vaporized state using low temperatures to vaporize the formulation. The formulation contains an inert non-reactive compound that lowers the heat of vaporization of the formulation, and the PDE-5 inhibitor. The formulation may optionally contain glycerin, alcohol, and/or water. Examples of inert non-reactive compounds that can sufficiently lower the heat of vaporization of the formulation include propylene glycol, vegetable glycerin and polysorbate. The formulation can be vaporized using a hand-held low temperature vaporizer or atomizer.

A method and formulation for delivering a PDE-5 inhibitor in a vaporized state using low temperatures to vaporize the formulation. The formulation contains an inert non-reactive compound that lowers the heat of vaporization of the formulation, and the PDE-5 inhibitor. The formulation may optionally contain glycerin, alcohol, and/or water. Examples of inert non-reactive compounds that can sufficiently lower the heat of vaporization of the formulation include propylene glycol, vegetable glycerin and polysorbate. The formulation can be vaporized using a hand-held low temperature vaporizer or atomizer.

A biochemical scaffold for regulating mammalian cell function, including a bioenergetic platform and a vibrational platform, the bioenergetic platform comprising a Krebs cycle modulator and/or glutathione modulator and/or neurotransmitter modulator and/or DNA modulator and/or endocannabinoid system modulator, the vibrational platform comprising at least one energy signature component, e.g. herb, that is subjected to harmonic oscillation in the range of approximately 23 Hz-1000 GHz for a period of time in the range of approximately 3-48 hrs.

A biochemical scaffold for regulating mammalian cell function, including a bioenergetic platform and a vibrational platform, the bioenergetic platform comprising a Krebs cycle modulator and/or glutathione modulator and/or neurotransmitter modulator and/or DNA modulator and/or endocannabinoid system modulator, the vibrational platform comprising at least one energy signature component, e.g. herb, that is subjected to harmonic oscillation in the range of approximately 23 Hz-1000 GHz for a period of time in the range of approximately 3-48 hrs.

A method and formulation for delivering a sexual aid, such as epimedium or yohimbe, in a vaporized state using low temperatures to vaporize the formulation. The formulation contains an inert non-reactive compound that lowers the heat of vaporization of the formulation, and the active compound. The formulation may optionally contain glycerin, alcohol, and/or water. Examples of inert non-reactive compounds that can sufficiently lower the heat of vaporization of the formulation include propylene glycol, vegetable glycerin and polysorbate. The formulation can be vaporized using a hand-held low temperature vaporizer or atomizer.

A method and formulation for delivering a sexual aid, such as epimedium or yohimbe, in a vaporized state using low temperatures to vaporize the formulation. The formulation contains an inert non-reactive compound that lowers the heat of vaporization of the formulation, and the active compound. The formulation may optionally contain glycerin, alcohol, and/or water. Examples of inert non-reactive compounds that can sufficiently lower the heat of vaporization of the formulation include propylene glycol, vegetable glycerin and polysorbate. The formulation can be vaporized using a hand-held low temperature vaporizer or atomizer.

The present invention provides methods and compositions for treating synaptic dysfunction and spinal cord injuries comprising, for example, the administration of a compound that increases the level of PZP in vivo.